Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 52 of 56 for:    insys

Cannabidiol as Adjunctive Treatment for Opioid Use Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03787628
Recruitment Status : Not yet recruiting
First Posted : December 25, 2018
Last Update Posted : March 29, 2019
Sponsor:
Information provided by (Responsible Party):
Edythe London, University of California, Los Angeles

Brief Summary:

This research aims to determine the effects and safety of cannabidiol (CBD) oral solution as an adjunctive therapy for patients, who have Opioid Use Disorder and are taking buprenorphine + naloxone. Buprenorphine + naloxone is an approved treatment for Opioid Use Disorder, but relapse to opioid misuse is common among patients who receive this treatment. Finding an adjunctive treatment that reduces relapse for these patients would be helpful.

Investigators will recruit participants from the Domiciliary treatment center at the West Los Angeles VA Medical Center (DOM). They will be receiving buprenorphine + naloxone as part of residential therapy. Potential participants who pass initial screening and wish to continue in the study will provide written, informed consent and will complete a 2-day evaluation, including blood and urine tests, questionnaires about their mood, medical, psychiatric and drug use history and physical exam.

Sixty participants who meet all eligibility criteria will be invited to complete baseline assessments (blood and urine tests, questionnaires), and will be assigned randomly to receive CBD or placebo in each of two cohorts, corresponding to two dose groups of 20 participants per cohort (CBD 700 , 1400 mg/day). Within each cohort, 20 participants will receive CBD and 10 will receive placebo. The cohorts will be studied in ascending dose order to ensure safety.

After the baseline measurements, participants will travel to UCLA by taxi, accompanied by a research associate, every morning for 4 weeks (28 sessions). Each morning, he or she will take the study medication under supervision (CBD 700, 1400 mg or placebo). Questionnaires on opioid craving, withdrawal, and mood symptoms will be administered daily during the treatment period.

After the 28-day intervention, participants will complete the questionnaires and undergo urine drug tests in 4 weekly follow-up visits.

The study will last ~10 weeks, comprising three periods: a screening period (2-weeks when participants are stabilized on buprenorphine + naloxone in residential treatment at the DOM), a treatment period (4 weeks when study CBD or placebo is administered at UCLA), and a follow-up period (4 weeks after termination of the test intervention).


Condition or disease Intervention/treatment Phase
Opioid-use Disorder Drug: Cannabidiol Oral Solution Drug: Placebo Phase 2

Detailed Description:

This will be a randomized, double-blind, placebo controlled, sequential, dose-ranging study of Cannabidiol Oral Solution (CBD) (700, 1400 mg/day) as an adjunctive therapy to buprenorphine + naloxone in patients who have Opioid Use Disorder and are receiving residential behavioral therapy, including cognitive behavioral therapy. The primary dependent variable will be cue-induced craving. Secondary measures will be reductions in spontaneous craving, opioid withdrawal, negative affective states, and relapse, as well as retention in treatment with buprenorphine + naloxone.

The study will be conducted at the Semel Institute in the David Geffen School of Medicine at the University of California Los Angeles (UCLA). Administration of the study compounds and all test procedures, and analyses will be conducted at UCLA.

Participants will be recruited from the Domiciliary Residential Rehabilitation Treatment Program of the Veterans Administration of Greater Los Angeles Health Center (the Dom).

This 300-bed program serves veterans with a wide range of psychiatric and medical conditions. More than 90% of those admitted to the program have been diagnosed with a substance use disorder. The Dom is staffed with psychiatrists, psychologists, social workers, recreation therapists, primary care physicians, and vocational rehabilitation specialists. It provides a therapeutic community that utilizes peer and professional support services in a structured, residential environment with 24-h and 7-days-a-week monitoring by on-site nurses and health technicians, who serve the needs of the patients and maintain communication. At the Dom, treatment as usual (TAU) for patients with Substance Use Disorder is 4 hours of group programming. Groups consist of various modalities, including cognitive behavioral therapy (CBT) for relapse prevention, Seeking Safety for Posttraumatic Stress Disorder,process groups, and Dialectical Behavioral Therapy. Matrix Model CBT, incorporating relapse prevention, is one of the core groups.

Sixty participants who meet all eligibility criteria will be randomized to receive CBD or placebo in each of two dose cohorts (30 participants per cohort): CBD 700 mg/day and 1400 mg/day. The cohorts will be studied sequentially according to ascending dose order to ensure safety. Within each cohort, participants will be randomized by baseline buprenorphine plasma level (either below or ≥ 2 ng/ml) so that 20 participants will receive active study medication and 10 will receive placebo. Thus, there will be 3 groups of 20 participants per treatment, including a group with 20 participants who receive placebo.

The study will comprise three periods: a 2-week screening period while participants are stabilized on buprenorphine + naloxone), a 4-week treatment period when study medication will be administered, and a 4-week follow-up period after termination of treatment with medication. Laboratory sessions will be conducted at three times: Day 0 (baseline), Day 7(when a steady state of CBD should have been reached; half-life of CBD after oral administration is 18-32 h),14 and Day 28 (end of treatment).

Adherence to medication in the trial will be assured as the participant will take the test medication (CBD or placebo) under supervision daily. Blood samples will be collected to determine plasma concentrations of CBD, buprenorphine and its metabolites as well as the endocannabinoids anandamide and 2-AG, which may contribute to the response to CBD, laboratory assessments of safety. Retention in treatment (this trial plus buprenorphine +naloxone) will be assessed over the 28-day medication (CBD or placebo) period and weekly follow-up assessments for the subsequent month (28-day follow-up period).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cannabidiol as Adjunctive Treatment for Opioid Use Disorder
Estimated Study Start Date : June 1, 2019
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : June 30, 2021

Arm Intervention/treatment
Experimental: Cannabidiol Oral Solution (CBD)
Sixty participants who meet all eligibility criteria will be randomized to receive CBD or placebo in each of three dose cohorts (30 participants per cohort): CBD 700 and 1400 mg/day. The cohorts will be studied sequentially according to ascending dose order to ensure safety.
Drug: Cannabidiol Oral Solution

CBD Oral Solution (700 and 1400 mg/day) or matching placebo will be administered orally once daily in the morning. The concentration of the CBD Oral Solution is 100 mg/ml.

Insys Development Company, Inc. has successfully manufactured a pharmaceutical grade, synthetic CBD drug substance. It is manufactured in Insys' current Good Manufacturing Practices (cGMP) manufacturing facility. This facility is approved by the Drug Enforcement Administration (DEA) and has been inspected by the Food and Drug Administration (FDA). This active pharmaceutical ingredient is ≥ 99.5% pure and can be consistently produced without concern for contaminant.


Placebo Comparator: Placebo
Within each cohort, participants will be randomized by baseline buprenorphine plasma level (either below or ≥ 2 ng/ml) so that 20 participants will receive active study medication and 10 will receive placebo. Thus, there will be 3 groups of 20 participants per treatment, including a group with 20 participants who receive placebo.
Drug: Placebo
The reference therapy will be placebo, consisting of an oral solution that matches the active test medication in appearance. Different volumes of placebo will be administered to match that of the active compound, daily in the morning for each of 28 days.




Primary Outcome Measures :
  1. Cue-induced opioid craving [ Time Frame: During the laboratory session before dosing on Day 0 (baseline without CBD) and on Days 7 and 28 after adjunctive treatment with CBD. ]
    Patients will be presented with 90 images, which consist of 40 heroin-related, 40 prescription-opioid-related and 10 neutral pictures. After the presentation of each cue, patients will rate their opioid craving by responding to 7 items derived from the Desire for Drug Questionnaire (DDQ).Each item is measured on a 7-point Likert scale, so that the craving score may range from 7 to 49. The primary outcome will be quantified as the change in craving response in the context of opioid cue-induced craving from the laboratory session before dosing on Day 0 (baseline without CBD) to Days 7 and 28 (after adjunctive treatment with CBD).


Secondary Outcome Measures :
  1. spontaneous opioid craving using the Penn Alcohol-Craving Scale adapted for opioid [ Time Frame: at baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks). ]
    A brief (5-item) unidimensional measure of craving. Items assess craving retrospectively during the week before testing. Responses can range from 0 to 6, and the scale is defined as the mean item score.Higher scores show higher levels of craving.

  2. Spielberger State-Trait Anxiety Inventory [ Time Frame: at baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks). ]
    A 40-item self-report rating scale for assessing anxiety. It comprises two subscales (each 20 items): the State Anxiety subscale evaluates how respondents feel "right now" and the Trait Anxiety subscale measures a generalized propensity to be anxious. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.

  3. Positive and Negative Affect Schedule (PANAS) [ Time Frame: at baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks). ]
    Affect is assessed using this 20-item questionnaire that measures both positive and negative affect. Each item is rated on a 5-point scale ranging from 1 (very slightly or not at all).

  4. Daily Opioid Craving [ Time Frame: at baseline before dosing(Day 0), daily during treatment period(28 days), and weekly during follow-up period (up to 4 weeks) ]
    Daily spontaneous opioid craving will be assessed using a 13-item questionnaire derived from the DDQ. Patients will be asked to rate their urge to use opioids ("How much do you want to use an opioid?") on a seven-step Likert-scale answer sheet based on what they feel or think at the moment. Patients indicate how much they agree or disagree with each of the statements on the questionnaire by placing a single checkmark along each line between STRONGLY DISAGREE and STRONGLY AGREE, so that the craving score may range from 7 to 49. Higher scores show higher levels of craving.

  5. plasma levels of buprenorphine and metabolites (norbuprenorphine and buprenorphine glucuronide) [ Time Frame: during the screening(2 weeks), at baseline (Day 0) and during the treatment period (28 days) and follow-up period (up to 2 weeks). ]
    Investigators will evaluate whether CBD might pose potential safety concerns associated with buprenorphine treatment. This study will seek to understand the drug-drug interaction for safe and effective treatment of Opioid Use Disorder and to identify an optimal adjunctive dose of CBD for patients receiving buprenorphine + naloxone treatment. Investigators predict a drug-drug interaction between CBD and buprenorphine, in which CBD will dose-dependently inhibit buprenorphine metabolism and therefore increase the ratio of buprenorphine/norbuprenorphine concentrations.

  6. plasma levels of anandamide and 2 AG [ Time Frame: At baseline(Day 0)and at the end of the treatment period(Day 28). ]
    Because CBD is an inhibitor of fatty acid amide hydrolase (FAAH), the principal enzyme catalyzing the catabolism of the major endocannabinoids (N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), administration of CBD may affect plasma concentrations of these endocannabinoids. Plasma levels of anandamide and 2-AG will be determined in order to obtain preliminary data on the extent to which CBD effects on the primary endpoints in the study reflect actions to increase anandamide and 2-AG concentrations. It is predicted that high baseline endocannabinoids will be associated with a smaller overall CBD effect and/or a maximum CBD effect at a lower dose.

  7. treatment retention [ Time Frame: throughout the study period(10 weeks). ]
    treatment retention as indicated by number of days of continued participation

  8. days of rescue medications [ Time Frame: throughout the 28-day treatment period ]
    days of rescue medications (e.g., clonidine, lofexidine, loperamide) for withdrawal symptoms

  9. CBD plasma levels [ Time Frame: during the treatment (28 days) and follow up period( up to 2 weeks). ]
    Plasma concentrations of CBD will be used to determine the pharmacokinetic (PK) parameters using noncompartmental PK analysis.

  10. Blood pressure [ Time Frame: on screening ( Day -14), at baseline (Day 0) and during the treatment period ( 28 days). ]
    Systolic and diastolic blood pressure will be monitored throughout the study.

  11. Heart rate [ Time Frame: on screening ( Day -14), at baseline (Day 0) and during the treatment period ( 28 days). ]
    Heart rate will be monitored throughout the study.

  12. Respiratory rate [ Time Frame: on screening ( Day -14), at baseline (Day 0) and during the treatment period ( 28 days). ]
    Respiratory rate will be monitored throughout the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 21 and 65 years old.
  2. Have an opiate use disorder that meets criteria set in the Mini-International Neuropsychiatric Interview (MINI 7.0.2) for DSM-5 over the last three months.
  3. Are on stable dose of buprenorphine maintenance therapy (buprenorphine 12-16 mg) for at least 7 days at the same maintenance dose.
  4. Report opioid use in the past 30 days.
  5. Ability to give valid, informed consent.
  6. Ability to speak and read English.
  7. If female of childbearing potential, agree to use of one of the following methods of birth control or be surgically sterile: oral contraceptives, patch, barrier (diaphragm or condom) with spermicide or condom only, intrauterine progesterone or non-hormonal contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse.

Exclusion Criteria:

  1. History of hypersensitivity to cannabidiol or any of the ingredients in the study drug.
  2. Received any medication within 30 days prior to enrollment that may induce or inhibit CYP3A4 or CYP2C19 that are main metabolic enzymes of CBD:

    1. Strong CYP3A4 inhibitors (boceprevir, cobicistat, conivaptan, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and ombitasvir and/or dasabuvir, posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, troleandomycin, voriconazole, clarithromycin, diltiazem, idelalisib, nefazodone, nelfinavir etc.);
    2. Moderate CYP3A4 inhibitors (aprepitant, cimetidine, ciprofloxacin, clotrimazole, crizotinib, cyclosporine, dronedarone, erythromycin, fluconazole, fluvoxamine, imatinib, tofisopam, verapamil etc.);
    3. Strong CYP2C19 inhibitors (fluoxetine, ticlopidine etc.);
    4. Strong CYP3A4 inducers carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort etc.); Strong CYP2C19 inducers (rifampin, ritonavir etc.).
  3. Current chronic use of a medication that may interact with cannabidiol (i.e., psychotropic medications such as benzodiazepines or anticonvulsants).
  4. Have a diagnosis of Drug Use Disorder (except for Opioid or Tobacco Use Disorder) in the past 3 months based on the Mini-International Neuropsychiatric Interview (MINI 7.0.2).
  5. Have a positive urine cannabis test at screening.
  6. Physiological dependence on alcohol or a sedative-hypnotic (e.g., a benzodiazepine that requires medical detoxification).
  7. Current maintenance treatment with methadone, or taking opioid antagonists such as naltrexone, except naloxone in combination with buprenorphine.
  8. Showing signs of acute opioid withdrawal symptoms.
  9. Clinically significant cardiovascular, hematologic, hepatic, renal, neurological, or endocrine abnormalities.
  10. Abnormal ovarian function assessment (hormonal battery or ovarian ultrasound findings) at baseline (Day 0).
  11. Have AIDS or current HIV treatment with antiviral and/or non-antiviral therapy.
  12. Be pregnant (+ HCG) or lactating.
  13. Have a history of head injury and neurological disease (stroke, neoplasia, benign tumor, arteriovenous malformation).
  14. Have unstable psychiatric conditions including suicidal ideation and behavior or have a history of recent suicidal attempts (within past year).
  15. Total bilirubin ≥ 1.5 x the upper limit of normal (ULN), alanine aminotransferase (ALT) ≥3 x ULN, aspartate aminotransferase (AST) ≥ 3 x ULN, serum creatinine > 2 x ULN, international normalized ratio (INR) >1.5 x ULN.
  16. Congenital long QT syndrome, history of prolonged QT in the 3 months prior to screening, or a corrected QT interval (Fridericia's - QTcF) >450 msec (male) or >470 msec (female) or history of risk factors for Torsades de Pointes.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787628


Contacts
Layout table for location contacts
Contact: Edythe London, PhD 3108250606 ELondon@mednet.ucla.edu
Contact: Anaheed Shirazi, MD 3108250606 ashirazi@mednet.ucla.edu

Sponsors and Collaborators
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Edythe London, PhD University of California, Los Angeles

Layout table for additonal information
Responsible Party: Edythe London, Professor in Residence, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT03787628     History of Changes
Other Study ID Numbers: 18-001748
First Posted: December 25, 2018    Key Record Dates
Last Update Posted: March 29, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Edythe London, University of California, Los Angeles:
Buprenorphine
Cannabidiol
Opioid Use disorder

Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Substance-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Pharmaceutical Solutions
Analgesics, Opioid
Buprenorphine
Epidiolex
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Anticonvulsants